Valuation: Relay Therapeutics, Inc.

Market Cap 4.27B 3.82B 3.53B 3.19B 5.97B 406B 6.06B 42.06B 16.78B 213B 16.01B 15.67B 673B P/E 2026 *
-12.1x
P/E 2027 * -12.1x
Enterprise Value 3.7B 3.31B 3.05B 2.76B 5.17B 352B 5.25B 36.44B 14.54B 184B 13.87B 13.58B 583B EV / Sales 2026 *
330x
EV / Sales 2027 * 214x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day-4.03%
1 week+3.30%
Current month+4.04%
1 month+4.04%
3 months-3.44%
6 months+44.91%
Current year+121.99%
1 week 17.82
Extreme 17.82
20.2
1 month 16.13
Extreme 16.13
20.2
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
6/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
8/9/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-4.06%+3.30%+155.86%+201.44% 4.27B
-0.62%+0.50%+33.92%+60.07% 64.38B
+1.34%+4.14%+15.97%+86.24% 56.16B
+0.45%+2.22%+15.65%+107.32% 54.16B
-2.73%-4.03%+23.86%+51.34% 45.33B
+0.53%-1.20%+20.95%+99.77% 42.25B
-0.51%+1.48%+222.32%+934.06% 40.78B
+2.96%+47.84%+112.50%+96.33% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.27%+4.86%+63.60%+167.67% 39.69B
Weighted average by Cap. +0.07%+3.67%+51.33%+162.81%

Financials

2026 *2027 *
Net sales 11.19M 10.02M 9.24M 8.36M 15.64M 1.07B 15.89M 110M 43.99M 557M 41.98M 41.08M 1.77B 17.91M 16.04M 14.8M 13.39M 25.05M 1.71B 25.45M 177M 70.45M 893M 67.22M 65.79M 2.83B
Net income -320M -287M -265M -239M -448M -30.48B -455M -3.16B -1.26B -15.95B -1.2B -1.18B -50.53B -347M -311M -287M -260M -486M -33.07B -494M -3.42B -1.37B -17.31B -1.3B -1.28B -54.82B
Net Debt -571M -511M -472M -427M -798M -54.35B -811M -5.63B -2.24B -28.44B -2.14B -2.1B -90.08B -442M -396M -365M -331M -618M -42.09B -628M -4.36B -1.74B -22.03B -1.66B -1.62B -69.77B
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
31/10/26 USD 18.76 -3.65% 362,497
29/10/26 USD 19.47 -1.12% 1,945,348
28/10/26 USD 19.69 +4.51% 2,808,741
27/10/26 USD 18.84 +3.97% 2,258,311
26/10/26 USD 18.12 -0.33% 1,585,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
19.47USD
Average target price
27.58USD
Spread / Average Target
+41.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock